{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T12:47:58Z","timestamp":1793969278486,"version":"4.8.0"},"reference-count":60,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T00:00:00Z","timestamp":1656633600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T00:00:00Z","timestamp":1656633600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,6,20]],"date-time":"2023-06-20T00:00:00Z","timestamp":1687219200000},"content-version":"am","delay-in-days":354,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100000062","name":"National Institute of Diabetes and Digestive and Kidney Diseases","doi-asserted-by":"publisher","award":["DK099052"],"award-info":[{"award-number":["DK099052"]}],"id":[{"id":"10.13039\/100000062","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000062","name":"National Institute of Diabetes and Digestive and Kidney Diseases","doi-asserted-by":"publisher","award":["DK118959"],"award-info":[{"award-number":["DK118959"]}],"id":[{"id":"10.13039\/100000062","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006483","name":"AbbVie","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006483","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007819","name":"Allergan","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007819","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000050","name":"National Heart, Lung, and Blood Institute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000050","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","gastrojournal.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Gastroenterology"],"published-print":{"date-parts":[[2022,7]]},"DOI":"10.1053\/j.gastro.2022.04.017","type":"journal-article","created":{"date-parts":[[2022,6,20]],"date-time":"2022-06-20T05:15:08Z","timestamp":1655702108000},"page":"137-151","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":192,"title":["AGA Clinical Practice Guideline on the Pharmacological Management of Irritable Bowel Syndrome With Diarrhea"],"prefix":"10.1053","volume":"163","author":[{"given":"Anthony","family":"Lembo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shahnaz","family":"Sultan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lin","family":"Chang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joel J.","family":"Heidelbaugh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Walter","family":"Smalley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G. Nicholas","family":"Verne","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1053\/j.gastro.2022.04.017_bib1","doi-asserted-by":"crossref","first-page":"712","DOI":"10.1016\/j.cgh.2012.02.029","article-title":"Global prevalence of and risk factors for irritable bowel syndrome: a meta-analysis","volume":"10","author":"Lovell","year":"2012","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1053\/j.gastro.2022.04.017_bib2","doi-asserted-by":"crossref","first-page":"1262","DOI":"10.1053\/j.gastro.2019.12.021","article-title":"Prevalence of Rome IV functional bowel disorders among adults in the United States, Canada, and the United Kingdom","volume":"158","author":"Palsson","year":"2020","journal-title":"Gastroenterology"},{"issue":"Suppl","key":"10.1053\/j.gastro.2022.04.017_bib3","doi-asserted-by":"crossref","first-page":"S98","DOI":"10.1097\/MCG.0b013e31821fbf44","article-title":"Quality of life in patients with irritable bowel syndrome","volume":"45","author":"Monnikes","year":"2011","journal-title":"J\u00a0Clin Gastroenterol"},{"key":"10.1053\/j.gastro.2022.04.017_bib4","doi-asserted-by":"crossref","first-page":"643","DOI":"10.2165\/00019053-200119060-00003","article-title":"Quality of life in irritable bowel syndrome","volume":"19","author":"Lea","year":"2001","journal-title":"Pharmacoeconomics"},{"key":"10.1053\/j.gastro.2022.04.017_bib5","doi-asserted-by":"crossref","first-page":"324","DOI":"10.5056\/jnm.2012.18.3.324","article-title":"Psychiatric, somatic and other functional gastrointestinal disorders in patients with irritable bowel syndrome at a tertiary care center","volume":"18","author":"Singh","year":"2012","journal-title":"J\u00a0Neurogastroenterol Motil"},{"key":"10.1053\/j.gastro.2022.04.017_bib6","first-page":"755","article-title":"A\u00a0systematic review of the economic and humanistic burden of illness in irritable bowel syndrome and chronic constipation","volume":"19","author":"Nellesen","year":"2013","journal-title":"J\u00a0Manag Care Pharm"},{"key":"10.1053\/j.gastro.2022.04.017_bib7","doi-asserted-by":"crossref","first-page":"8103","DOI":"10.3748\/wjg.v21.i26.8103","article-title":"Patients with irritable bowel syndrome-diarrhea have lower disease-specific quality of life than irritable bowel syndrome-constipation","volume":"21","author":"Singh","year":"2015","journal-title":"World J Gastroenterol"},{"key":"10.1053\/j.gastro.2022.04.017_bib8","doi-asserted-by":"crossref","first-page":"1569","DOI":"10.1007\/BF01303162","article-title":"U.S. householder survey of functional gastrointestinal disorders. Prevalence, sociodemography, and health impact","volume":"38","author":"Drossman","year":"1993","journal-title":"Dig Dis Sci"},{"key":"10.1053\/j.gastro.2022.04.017_bib9","doi-asserted-by":"crossref","first-page":"1540","DOI":"10.1038\/s41395-018-0262-x","article-title":"Work productivity and activity impairment in irritable bowel syndrome (IBS): a multifaceted problem","volume":"113","author":"Frandemark","year":"2018","journal-title":"Am J Gastroenterol"},{"key":"10.1053\/j.gastro.2022.04.017_bib10","doi-asserted-by":"crossref","first-page":"1726","DOI":"10.1016\/j.clinthera.2006.10.010","article-title":"Health-related quality of life, work productivity, and health care resource utilization of subjects with irritable bowel syndrome: baseline results from LOGIC (Longitudinal Outcomes Study of Gastrointestinal Symptoms in Canada), a naturalistic study","volume":"28","author":"Pare","year":"2006","journal-title":"Clin Ther"},{"key":"10.1053\/j.gastro.2022.04.017_bib11","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1046\/j.1365-2036.2003.01456.x","article-title":"The prevalence, patterns and impact of irritable bowel syndrome: an international survey of 40,000 subjects","volume":"17","author":"Hungin","year":"2003","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1053\/j.gastro.2022.04.017_bib12","doi-asserted-by":"crossref","first-page":"1365","DOI":"10.1111\/j.1365-2036.2005.02463.x","article-title":"Irritable bowel syndrome in the United States: prevalence, symptom patterns and impact","volume":"21","author":"Hungin","year":"2005","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1053\/j.gastro.2022.04.017_bib13","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1053\/j.gastro.2020.04.014","article-title":"Worldwide prevalence and burden of functional gastrointestinal disorders, results of Rome Foundation Global Study","volume":"160","author":"Sperber","year":"2021","journal-title":"Gastroenterology"},{"key":"10.1053\/j.gastro.2022.04.017_bib14","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1053\/j.gastro.2019.07.004","article-title":"AGA Clinical Practice Guidelines on the laboratory evaluation of functional diarrhea and diarrhea-predominant irritable bowel syndrome in adults (IBS-D)","volume":"157","author":"Smalley","year":"2019","journal-title":"Gastroenterology"},{"key":"10.1053\/j.gastro.2022.04.017_bib15","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1053\/j.gastro.2019.06.014","article-title":"AGA Technical Review on the evaluation of functional diarrhea and diarrhea-predominant irritable bowel syndrome in adults (IBS-D)","volume":"157","author":"Carrasco-Labra","year":"2019","journal-title":"Gastroenterology"},{"key":"10.1053\/j.gastro.2022.04.017_bib16","series-title":"Rome IV Diagnostic Algorithms for Common GI Symptoms","year":"2016"},{"key":"10.1053\/j.gastro.2022.04.017_bib17","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.1053\/j.gastro.2014.09.002","article-title":"American Gastroenterological Association Institute Technical Review on the pharmacological management of irritable bowel syndrome","volume":"147","author":"Chang","year":"2014","journal-title":"Gastroenterology"},{"key":"10.1053\/j.gastro.2022.04.017_bib18","doi-asserted-by":"crossref","first-page":"1146","DOI":"10.1053\/j.gastro.2014.09.001","article-title":"American Gastroenterological Association Institute Guideline on the pharmacological management of irritable bowel syndrome","volume":"147","author":"Weinberg","year":"2014","journal-title":"Gastroenterology"},{"key":"10.1053\/j.gastro.2022.04.017_bib19","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1016\/j.cgh.2013.02.001","article-title":"The AGA institute process for developing clinical practice guidelines part one: grading the evidence","volume":"11","author":"Sultan","year":"2013","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1053\/j.gastro.2022.04.017_bib20","doi-asserted-by":"crossref","first-page":"920","DOI":"10.3109\/00365529709011203","article-title":"Stool form scale as a useful guide to intestinal transit time","volume":"32","author":"Lewis","year":"1997","journal-title":"Scand J Gastroenterol"},{"key":"10.1053\/j.gastro.2022.04.017_bib21","doi-asserted-by":"crossref","first-page":"1442","DOI":"10.1111\/j.1572-0241.2007.01283.x","article-title":"Characterization of health related quality of life (HRQOL) for patients with functional bowel disorder (FBD) and its response to treatment","volume":"102","author":"Drossman","year":"2007","journal-title":"Am J Gastroenterol"},{"key":"10.1053\/j.gastro.2022.04.017_bib22","series-title":"Cochrane Handbook for Systematic Reviews of Interventions, Version 5.1.0","year":"2011"},{"key":"10.1053\/j.gastro.2022.04.017_bib23","author":"Brozek"},{"key":"10.1053\/j.gastro.2022.04.017_bib24","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.1111\/j.1476-5381.2012.02068.x","article-title":"Modulation of gastrointestinal function by MuDelta, a mixed micro opioid receptor agonist\/ micro opioid receptor antagonist","volume":"167","author":"Wade","year":"2012","journal-title":"Br J Pharmacol"},{"key":"10.1053\/j.gastro.2022.04.017_bib25","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1053\/j.gastro.2013.04.006","article-title":"Eluxadoline benefits patients with irritable bowel syndrome with diarrhea in a phase 2 study","volume":"145","author":"Dove","year":"2013","journal-title":"Gastroenterology"},{"key":"10.1053\/j.gastro.2022.04.017_bib26","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1053\/j.gastro.2016.08.003","article-title":"Repeat treatment with rifaximin is safe and effective in patients with diarrhea-predominant irritable bowel syndrome","volume":"151","author":"Lembo","year":"2016","journal-title":"Gastroenterology"},{"key":"10.1053\/j.gastro.2022.04.017_bib27","doi-asserted-by":"crossref","first-page":"1393","DOI":"10.1053\/j.gastro.2016.02.031","article-title":"Bowel disorders","volume":"150","author":"Mearin","year":"2016","journal-title":"Gastroenterology"},{"key":"10.1053\/j.gastro.2022.04.017_bib29","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1056\/NEJMoa1004409","article-title":"Rifaximin therapy for patients with irritable bowel syndrome without constipation","volume":"364","author":"Pimentel","year":"2011","journal-title":"N\u00a0Engl J Med"},{"key":"10.1053\/j.gastro.2022.04.017_bib30","doi-asserted-by":"crossref","first-page":"A-545","DOI":"10.1016\/S0016-5085(08)62544-5","article-title":"Rifaximin for the treatment of diarrhea-associated irritable bowel syndrome: short term treatment leading to long term sustained response","volume":"134","author":"Lembo","year":"2008","journal-title":"Gastroenterology"},{"key":"10.1053\/j.gastro.2022.04.017_bib31","doi-asserted-by":"crossref","first-page":"1480","DOI":"10.1053\/j.gastro.2005.11.061","article-title":"Functional bowel disorders","volume":"130","author":"Longstreth","year":"2006","journal-title":"Gastroenterology"},{"key":"10.1053\/j.gastro.2022.04.017_bib32","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1177\/1756283X17726087","article-title":"Repeat treatment with rifaximin improves irritable bowel syndrome-related quality of life: a secondary analysis of a randomized, double-blind, placebo-controlled trial","volume":"10","author":"Cash","year":"2017","journal-title":"Therap Adv Gastroenterol"},{"key":"10.1053\/j.gastro.2022.04.017_bib33","doi-asserted-by":"crossref","first-page":"1161","DOI":"10.1111\/apt.12735","article-title":"Safety and tolerability of rifaximin for the treatment of irritable bowel syndrome without constipation: a pooled analysis of randomised, double-blind, placebo-controlled trials","volume":"39","author":"Schoenfeld","year":"2014","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1053\/j.gastro.2022.04.017_bib34","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1111\/j.1365-2036.2008.03721.x","article-title":"Neural and psychological predictors of treatment response in irritable bowel syndrome patients with a 5-HT3 receptor antagonist: a pilot study","volume":"28","author":"Jarcho","year":"2008","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1053\/j.gastro.2022.04.017_bib35","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1177\/1756283X13491798","article-title":"A\u00a09-year evaluation of temporal trends in alosetron postmarketing safety under the risk management program","volume":"6","author":"Tong","year":"2013","journal-title":"Therap Adv Gastroenterol"},{"key":"10.1053\/j.gastro.2022.04.017_bib36","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.1046\/j.1365-2036.1999.00610.x","article-title":"Improvement in pain and bowel function in female irritable bowel patients with alosetron, a 5-HT3 receptor antagonist","volume":"13","author":"Camilleri","year":"1999","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1053\/j.gastro.2022.04.017_bib37","doi-asserted-by":"crossref","first-page":"1035","DOI":"10.1016\/S0140-6736(00)02033-X","article-title":"Efficacy and safety of alosetron in women with irritable bowel syndrome: a randomised, placebo-controlled trial","volume":"355","author":"Camilleri","year":"2000","journal-title":"Lancet"},{"key":"10.1053\/j.gastro.2022.04.017_bib38","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1111\/j.1572-0241.2005.40365.x","article-title":"A\u00a0dose-ranging, phase II study of the efficacy and safety of alosetron in men with diarrhea-predominant IBS","volume":"100","author":"Chang","year":"2005","journal-title":"Am J Gastroenterol"},{"key":"10.1053\/j.gastro.2022.04.017_bib39","doi-asserted-by":"crossref","first-page":"1709","DOI":"10.1111\/j.1572-0241.2007.01282.x","article-title":"A\u00a0randomized, double-blind, placebo-controlled study to assess efficacy and safety of 0.5 mg and 1 mg alosetron in women with severe diarrhea-predominant IBS","volume":"102","author":"Krause","year":"2007","journal-title":"Am J Gastroenterol"},{"key":"10.1053\/j.gastro.2022.04.017_bib40","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1046\/j.1365-2036.2000.00684.x","article-title":"A\u00a0double-blind, randomized, placebo-controlled dose-ranging study to evaluate the efficacy of alosetron in the treatment of irritable bowel syndrome","volume":"14","author":"Bardhan","year":"2000","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1053\/j.gastro.2022.04.017_bib41","doi-asserted-by":"crossref","first-page":"1733","DOI":"10.1001\/archinte.161.14.1733","article-title":"A\u00a0randomized controlled clinical trial of the serotonin type 3 receptor antagonist alosetron in women with diarrhea-predominant irritable bowel syndrome","volume":"161","author":"Camilleri","year":"2001","journal-title":"Arch Intern Med"},{"key":"10.1053\/j.gastro.2022.04.017_bib42","doi-asserted-by":"crossref","first-page":"2662","DOI":"10.1111\/j.1572-0241.2001.04128.x","article-title":"Alosetron controls bowel urgency and provides global symptom improvement in women with diarrhea-predominant irritable bowel syndrome","volume":"96","author":"Lembo","year":"2001","journal-title":"Am J Gastroenterol"},{"key":"10.1053\/j.gastro.2022.04.017_bib43","doi-asserted-by":"crossref","first-page":"2195","DOI":"10.1111\/j.1572-0241.2004.30509.x","article-title":"Long-term safety and efficacy of alosetron in women with severe diarrhea-predominant irritable bowel syndrome","volume":"99","author":"Chey","year":"2004","journal-title":"Am J Gastroenterol"},{"key":"10.1053\/j.gastro.2022.04.017_bib44","doi-asserted-by":"crossref","first-page":"77","DOI":"10.3109\/00365528709091003","article-title":"Loperamide in treatment of irritable bowel syndrome-adouble-blind placebo controlled study","volume":"130","author":"Lav\u00f6","year":"1987","journal-title":"Scand J Gastroenterol Suppl"},{"key":"10.1053\/j.gastro.2022.04.017_bib45","doi-asserted-by":"crossref","first-page":"81","DOI":"10.3109\/00365528709091004","article-title":"Loperamide treatment of the irritable bowel syndrome","volume":"130","author":"Hovdenak","year":"1987","journal-title":"Scand J Gastroenterol Suppl"},{"key":"10.1053\/j.gastro.2022.04.017_bib46","doi-asserted-by":"crossref","first-page":"1257","DOI":"10.1053\/j.gastro.2016.03.035","article-title":"Rome IV-functional GI disorders: disorders of gut-brain interaction","volume":"150","author":"Drossman","year":"2016","journal-title":"Gastroenterology"},{"key":"10.1053\/j.gastro.2022.04.017_bib47","doi-asserted-by":"crossref","first-page":"1140","DOI":"10.1053\/j.gastro.2017.11.279","article-title":"Neuromodulators for functional gastrointestinal disorders (disorders of gut-brain interaction): a Rome Foundation Working Team Report","volume":"154","author":"Drossman","year":"2018","journal-title":"Gastroenterology"},{"key":"10.1053\/j.gastro.2022.04.017_bib48","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1111\/j.1365-2036.2008.03633.x","article-title":"Clinical trial: the effect of amitriptyline in patients with diarrhoea-predominant irritable bowel syndrome","volume":"27","author":"Vahedi","year":"2008","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1053\/j.gastro.2022.04.017_bib49","doi-asserted-by":"crossref","first-page":"1095","DOI":"10.1136\/gut.2005.077503","article-title":"A\u00a0controlled crossover study of the selective serotonin reuptake inhibitor citalopram in irritable bowel syndrome","volume":"55","author":"Tack","year":"2006","journal-title":"Gut"},{"key":"10.1053\/j.gastro.2022.04.017_bib50","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1016\/S1542-3565(03)70039-1","article-title":"The selective serotonin reuptake inhibitor fluoxetine does not change rectal sensitivity and symptoms in patients with irritable bowel syndrome: a double blind, randomized, placebo-controlled study","volume":"1","author":"Kuiken","year":"2003","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1053\/j.gastro.2022.04.017_bib51","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/j.cgh.2009.09.008","article-title":"Citalopram provides little or no benefit in nondepressed patients with irritable bowel syndrome","volume":"8","author":"Ladabaum","year":"2010","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1053\/j.gastro.2022.04.017_bib52","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1176\/appi.psy.50.1.78","article-title":"A\u00a0double-blind, randomized, placebo-controlled trial of paroxetine controlled-release in irritable bowel syndrome","volume":"50","author":"Masand","year":"2009","journal-title":"Psychosomatics"},{"key":"10.1053\/j.gastro.2022.04.017_bib53","doi-asserted-by":"crossref","first-page":"914","DOI":"10.1111\/j.1572-0241.2004.04127.x","article-title":"Paroxetine to treat irritable bowel syndrome not responding to high-fiber diet: a double-blind, placebo-controlled trial","volume":"99","author":"Tabas","year":"2004","journal-title":"Am J Gastroenterol"},{"key":"10.1053\/j.gastro.2022.04.017_bib54","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1007\/s10620-007-9830-4","article-title":"Antidepressant therapy (imipramine and citalopram) for irritable bowel syndrome: a double-blind, randomized, placebo-controlled trial","volume":"53","author":"Talley","year":"2008","journal-title":"Dig Dis Sci"},{"key":"10.1053\/j.gastro.2022.04.017_bib55","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1016\/j.coph.2008.07.012","article-title":"Psychotropic agents in functional gastrointestinal disorders","volume":"8","author":"Grover","year":"2008","journal-title":"Curr Opin Pharmacol"},{"key":"10.1053\/j.gastro.2022.04.017_bib56","first-page":"17","article-title":"Interactions between symptoms and motor and visceral sensory responses of irritable bowel syndrome patients to spasmolytics (antispasmodics)","volume":"18","author":"Khalif","year":"2009","journal-title":"J\u00a0Gastrointestin Liver Dis"},{"key":"10.1053\/j.gastro.2022.04.017_bib57","first-page":"CD003460","article-title":"Bulking agents, antispasmodics and antidepressants for the treatment of irritable bowel syndrome","author":"Ruepert","year":"2011","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1053\/j.gastro.2022.04.017_bib58","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1053\/j.gastro.2020.05.059","article-title":"AGA Clinical Practice Guidelines on the role of probiotics in the management of gastrointestinal disorders","volume":"159","author":"Su","year":"2020","journal-title":"Gastroenterology"},{"key":"10.1053\/j.gastro.2022.04.017_bib59","doi-asserted-by":"crossref","first-page":"1481","DOI":"10.1053\/j.gastro.2016.02.014","article-title":"Rome IV diagnostic questionnaires and tables for investigators and clinicians","volume":"150","author":"Palsson","year":"2016","journal-title":"Gastroenterology"},{"key":"10.1053\/j.gastro.2022.04.017_bib60","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1016\/j.cgh.2021.06.032","article-title":"The transition from Rome III to Rome IV irritable bowel syndrome: what we gain and lose","volume":"20","author":"Shin","year":"2022","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1053\/j.gastro.2022.04.017_bib63","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1016\/j.jval.2016.11.001","article-title":"Development of the diary for irritable bowel syndrome symptoms to assess treatment benefit in clinical trials: foundational qualitative research","volume":"20","author":"Fehnel","year":"2017","journal-title":"Value Health"}],"container-title":["Gastroenterology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0016508522003912?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0016508522003912?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,3]],"date-time":"2025-11-03T09:51:12Z","timestamp":1762163472000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0016508522003912"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,7]]},"references-count":60,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,7]]}},"alternative-id":["S0016508522003912"],"URL":"https:\/\/doi.org\/10.1053\/j.gastro.2022.04.017","relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.742243416.793594347","asserted-by":"object"}]},"ISSN":["0016-5085"],"issn-type":[{"value":"0016-5085","type":"print"}],"subject":[],"published":{"date-parts":[[2022,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"AGA Clinical Practice Guideline on the Pharmacological Management of Irritable Bowel Syndrome With Diarrhea","name":"articletitle","label":"Article Title"},{"value":"Gastroenterology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1053\/j.gastro.2022.04.017","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 by the AGA Institute","name":"copyright","label":"Copyright"}]}}